Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Di Avellino, Avellino, Italy, presents encouraging data on the anti-complement agent iptacopan for treating paroxysmal nocturnal hemoglobinuria…
Barbara Burton, MD, Northwestern University, discusses enzyme replacement therapy in patients with mucopolysaccharidosis (MPS) IVA.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy derived from thymic T-cell precursors. Approximately 40-60% of T-ALL cases exhibit aberrant overexpression of the TAL1…
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study…
Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.